

02/21/02
JC928 U.S. PTO.

Please type a plus sign (+) inside this box →



02/25/02 10:43:11 023102

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No 16336.002	
		First Inventor VIVIEN W. CHAN	
		Title GENE PRODUCTS DIFFERENTIALLY EXPRESSED CANCEROUS COLON CELLS AND THEIR METHODS OF USE	
		Express Mail Label No. EL 779 660 531 US	

APPLICATION ELEMENTS SEE MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
--	--

1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original and a duplicate for fee processing)</small> 2. <input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27 3. <input checked="" type="checkbox"/> Specification [Total Pages 393] <small>(preferred arrangement set forth below)</small> -Descriptive title of the invention -Cross Reference to Related Applications -Statement Regarding Fed sponsored R & D -Reference to sequence listing, a table, or a computer program listing appendix -Background of the Invention -Brief Summary of the Invention -Brief Description of the Drawings (if filed) -Detailed Description -Claim(s) -Abstract of the Disclosure 4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Pages: _____] 5. Oath or Declaration [Total Pages: _____] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63 (d)) <small>(for continuation/divisional with Box 18 completed)</small> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) Named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b) 6. <input checked="" type="checkbox"/> Application Data Sheet See 37 CFR 1.76	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small> a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on i. <input checked="" type="checkbox"/> CD-ROM or CD-R (2 copies), or ii. <input type="checkbox"/> paper c. <input checked="" type="checkbox"/> Statements verifying identity of above copies
--	---

ACCOMPANYING APPLICATION PARTS
9. <input type="checkbox"/> Assignment Papers (cover sheet & documents(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small> 11. <input type="checkbox"/> English Translation Document (if applicable) 12. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Citations Statement (IDS)/PTO-1449 13. <input type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 16. <input checked="" type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent 17. <input type="checkbox"/> Other. _____

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Prior application information: Examiner: _____ Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. **The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.**

19. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label	24353	or <input type="checkbox"/> Correspondence address below
<small>(Insert Customer No. or Attach bar code label here)</small>		

Name	Carol L. Francis				
	BOZICEVIC, FIELD & FRANCIS LLP				
Address	200 Middlefield Road, Suite 200				
City	Menlo Park	State	California	Zip Code	94025
Country	U.S.A.	Telephone	(650) 327-3400	Fax	(650) 327-3231
Name	Carol L. Francis	Registration No. (Attorney/Agent)	36,513		
Signature		Date	Feb 21, 2002		

Burden Hour Statement This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

CERTIFICATION REGARDING SEQUENCE LISTING

Application Number	Unassigned
Confirmation Number	N/A
Filing Date	Herewith (February 21, 2002)
First Named Inventor	Vivien W. Chan et al.
Examiner	Unassigned
Group Art	Unassigned
Attorney Docket No.	16336.002


ADDRESS TO: Assistant Commissioner for Patents
Washington, D.C. 20231

As required by 37 § C.F.R. 1.821(f), all information on CD 'Copy 1', 'Copy 2' and 'CRF' is identical. I hereby certify that the enclosed submission includes no new matter. The Sequence Listing was prepared with the software FASTSEQ, and conforms to the Patent Office guidelines.

Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number 16336.002.

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815, Order No. 16336.002. If additional fees are required, including extensions of time, please consider this a petition therefore.

Name (Print/Type)	Carol L. Francis	Registration No.	36,513		
Signature		Date	02-21-2002		
Firm Name	Bozicevic, Field & Francis LLP	Address	200 Middlefield Road, Suite 200		
City	Menlo Park	State	California	zip	94025
Telephone - Direct Dial	650-833-7713	Facsimile	650-327-3231		

EXPRESS MAIL LABEL NO. 779 660 531 US

EXPRESS MAIL LABEL NO. EL 779 660 531 US

NONPUBLICATION REQUEST UNDER 35 U.S.C. 122(b)(2)(B)(i)	First Named Inventor	Vivien W. Chan
	Atty Docket Number	16336.002
	Title:	<i>"GENE PRODUCTS DIFFERENTIALLY EXPRESSED IN CANCEROUS COLON CELLS AND THEIR METHODS OF USE"</i>

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

February 21, 2002
Date

Carol L. Francis
Signature

Carol L. Francis
Typed or Printed Name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**